argenx (NASDAQ:ARGX)‘s stock had its “average” rating reaffirmed by analysts at Stifel Nicolaus in a note issued to investors on Thursday, January 9th, AnalystRatings.com reports.
Several other research analysts have also recently issued reports on the stock. Zacks Investment Research upgraded shares of argenx from a “hold” rating to a “buy” rating and set a $180.00 target price on the stock in a report on Thursday, January 2nd. Wells Fargo & Co initiated coverage on shares of argenx in a research report on Friday, September 27th. They issued a “market perform” rating and a $125.00 price objective for the company. Piper Jaffray Companies increased their price objective on shares of argenx from $177.00 to $194.00 and gave the company an “overweight” rating in a research report on Monday, January 6th. Credit Suisse Group initiated coverage on shares of argenx in a research report on Tuesday, November 5th. They issued a “neutral” rating and a $137.00 price objective for the company. Finally, Cowen initiated coverage on shares of argenx in a research report on Friday, September 13th. They issued a “buy” rating for the company. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and eleven have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $168.25.
argenx stock traded down $0.44 during midday trading on Thursday, hitting $151.03. 1,993 shares of the company’s stock were exchanged, compared to its average volume of 134,229. argenx has a 12 month low of $100.20 and a 12 month high of $169.50. The firm has a 50-day moving average of $156.77 and a two-hundred day moving average of $137.44. The company has a market cap of $5.85 billion, a PE ratio of -64.10 and a beta of 1.25.
argenx Company Profile
argenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company's lead product candidates include ARGX-113 that completed Phase 2 clinical trials for the treatment of autoimmune diseases, including myasthenia gravis, immune thrombocytopenia, and pemphigus vulgaris; and ARGX-110, which is in Phase 1/2 clinical trials for the treatment of T-cell lymphoma, acute myeloid leukemia, and myelodysplastic syndrome.
Recommended Story: What sectors are represented in the FTSE 100 index?
Receive News & Ratings for argenx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for argenx and related companies with MarketBeat.com's FREE daily email newsletter.